Tucatinib 50mg Tablets$269.00
1–9 boxes
$269.00 each
10–24 boxes
8% off
25+ boxes
10% off
Tucatinib 50mg Tablets
SKU GME1118Oncology Care
Product Introduction
Tucatinib 50mg is a targeted HER2 inhibitor used with trastuzumab and capecitabine for previously treated advanced HER2-positive breast cancer, including disease involving the brain. It is also used with trastuzumab in an appropriate previously treated HER2-positive, RAS-wild-type colorectal-cancer regimen.
How to use
Take the tablets twice daily, about 12 hours apart, with or without food. Swallow them whole. The daily regimen may require more than one tablet per dose.
How it works
Tucatinib inhibits the kinase activity of HER2, a receptor that can drive cancer-cell growth. Blocking HER2 signalling interferes with proliferation of HER2-dependent tumour cells.
Side effects
Diarrhoea, nausea, fatigue and liver-test abnormalities can occur. Capecitabine in the combination can also cause hand-foot symptoms and mouth sores. Severe diarrhoea with dehydration or jaundice requires prompt treatment.
Important information
HER2 testing establishes tumour eligibility. Liver enzymes and bilirubin are checked before treatment and regularly during therapy, commonly every three weeks. Rifampicin, gemfibrozil and several other enzyme or transporter-interacting medicines can substantially change drug exposure.
Uses
- HER2-positive advanced or metastatic breast cancer in the appropriate trastuzumab/capecitabine regimen
- selected previously treated HER2-positive, RAS-wild-type colorectal cancer with trastuzumab.
Benefits
Adds HER2-directed treatment to improve disease control in responsive cancers. The breast-cancer combination also has activity when the cancer has spread to the brain.
Why is HER2 testing needed before treatment?
Tucatinib targets HER2 signalling. A cancer without the relevant HER2 expression or amplification is not assumed to respond simply because it arises in the breast or bowel.
Can a rise in creatinine always be interpreted as kidney injury?
Tucatinib can raise creatinine by inhibiting its tubular secretion without reducing actual filtration. Dehydration can still cause true injury, so the result is interpreted with symptoms and other renal measures.
Should diarrhoea wait until the next blood-test visit?
No. Early fluid replacement and the prescribed diarrhoea-treatment plan can prevent dehydration. Frequent watery stools, dizziness or inability to drink needs prompt help.
What if I miss or vomit a tucatinib dose?
Skip that dose and take the next dose at its usual scheduled time. Do not take an extra tablet after vomiting or double the next dose to catch up.
HER2: receptor driving growth in certain tumours. Kinase inhibitor: medicine blocking an enzyme-mediated signal. Brain metastasis: cancer spread to the brain. RAS wild-type: absence of relevant RAS mutations. Tubular secretion: movement of substances from blood into urine by kidney tubules.; AR: Tucatinib 50mg أقراص; FR: Tucatinib 50mg comprimés; PT: Tucatinib 50mg comprimidos; ES: Tucatinib 50mg comprimidos; RU: Tucatinib 50mg таблетки; ID: Tucatinib 50mg tablet; VI: Tucatinib 50mg viên nén; MS: Tucatinib 50mg tablet; TL: Tucatinib 50mg tableta; ZH-SG: Tucatinib 50mg 片剂